Long-term treatment with human growth hormone, also known as somatropin, does not seem to influence mortality in people with Prader-Willi syndrome (PWS), but may increase the risk of developing type 2 diabetes, a study from South Korea found. The risk of type 2 diabetes increased by 6%…
A Phase 3 clinical trial testing ACP-101 for hyperphagia, or uncontrollable hunger, in Prader-Willi syndrome (PWS) patients failed to meet its primary and secondary goals. Top-line results from the trial of Acadia Pharmaceuticals’ experimental nasal spray, dubbed COMPASS PWS (NCT06173531), showed no significant differences between the ACP-101…
Adults with Prader-Willi syndrome (PWS) caused by a genetic deletion have higher obesity rates and more severe obesity than those with PWS associated with other genetic abnormalities, a study found. “Given the higher risk of obesity observed in individuals with the deletion subtype, our results support the need for…
Early findings from a Phase 2 clinical trial testing Rhythm Pharmaceuticals’ setmelanotide in children and adults with obesity due to Prader-Willi syndrome (PWS) are expected this year. That’s according to an update from Rhythm, which announced in a company press release that it plans to “disclose preliminary…
Get regular updates to your inbox.
